JPMorgan Chase & Co. increased its price target for Eli Lilly and Company to $1,400 from $1,300, maintaining an "overweight" rating on the stock. The new target suggests a potential upside of approximately 16.6% from the company's previous closing price. This optimistic outlook is rooted in the strong and sustained demand for the company's popular GLP-1 drugs for diabetes and weight loss, Mounjaro and Zepbound.
The analyst action comes as investor sentiment is buoyed by recent positive developments, including the expansion of Medicare coverage for weight-loss drugs through a new bridge program, which is expected to widen patient access significantly. While the stock has seen substantial gains over the past year, analysts point to the company's robust drug pipeline and market leadership as key drivers for continued growth.